The Increasing Complexity of the Oncofetal H19 Gene Locus: Functional Dissection and Therapeutic Intervention

被引:81
作者
Matouk, Imad [1 ,2 ]
Raveh, Eli [1 ]
Ohana, Patricia [1 ]
Abu Lail, Rasha [1 ]
Gershtain, Eitan [1 ]
Gilon, Michal [1 ]
De Groot, Nathan [1 ]
Czerniak, Abraham [3 ]
Hochberg, Abraham [1 ]
机构
[1] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel
[2] Al Quds Univ, Fac Sci & Technol, Dept Biol Sci, IL-51000 Jerusalem, Israel
[3] Chaim Sheba Med Ctr, Dept HPB Surg A, IL-52621 Tel Hashomer, Israel
来源
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2013年 / 14卷 / 02期
关键词
long non-coding RNA; transcriptional modulators; DNA-based therapy; diphtheria toxin A; sense and antisense transcripts; BECKWITH-WIEDEMANN-SYNDROME; NONCODING RNA; RHEUMATOID-ARTHRITIS; ANTISENSE TRANSCRIPT; CELL-PROLIFERATION; TUMOR-GROWTH; CANCER; PREECLAMPSIA; EXPRESSION; MIR-675;
D O I
10.3390/ijms14024298
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The field of the long non-coding RNA (lncRNA) is advancing rapidly. Currently, it is one of the most popular fields in the biological and medical sciences. It is becoming increasingly obvious that the majority of the human transcriptome has little or no-protein coding capacity. Historically, H19 was the first imprinted non-coding RNA (ncRNA) transcript identified, and the H19/IGF2 locus has served as a paradigm for the study of genomic imprinting since its discovery. In recent years, we have extensively investigated the expression of the H19 gene in a number of human cancers and explored the role of H19 RNA in tumor development. Here, we discuss recently published data from our group and others that provide further support for a central role of H19 RNA in the process of tumorigenesis. Furthermore, we focus on major transcriptional modulators of the H19 gene and discuss them in the context of the tumor-promoting activity of the H19 RNA. Based on the pivotal role of the H19 gene in human cancers, we have developed a DNA-based therapeutic approach for the treatment of cancers that have upregulated levels of H19 expression. This approach uses a diphtheria toxin A (DTA) protein expressed under the regulation of the H19 promoter to treat tumors with significant expression of H19 RNA. In this review, we discuss the treatment of four cancer indications in human subjects using this approach, which is currently under development. This represents perhaps one of the very few examples of an existing DNA-based therapy centered on an lncRNA system. Apart from cancer, H19 expression has been reported also in other conditions, syndromes and diseases, where deregulated imprinting at the H19 locus was obvious in some cases and will be summarized below. Moreover, the H19 locus proved to be much more complicated than initially thought. It houses a genomic sequence that can transcribe, yielding various transcriptional outputs, both in sense and antisense directions. The major transcriptional outputs of the H19 locus are presented here.
引用
收藏
页码:4298 / 4316
页数:19
相关论文
共 47 条
  • [1] Adam GIR, 1996, DEVELOPMENT, V122, P839
  • [2] Possible physiological role of H19 RNA
    Ayesh, S
    Matouk, I
    Schneider, T
    Ohana, P
    Laster, M
    Al-Sharef, W
    de-Groot, N
    Hochberg, A
    [J]. MOLECULAR CARCINOGENESIS, 2002, 35 (02) : 63 - 74
  • [3] The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis
    Barsyte-Lovejoy, Dalia
    Lau, Suzanne K.
    Boutros, Paul C.
    Khosravi, Fereshteh
    Jurisica, Igor
    Andrulis, Irene L.
    Tsao, Ming S.
    Penn, Linda Z.
    [J]. CANCER RESEARCH, 2006, 66 (10) : 5330 - 5337
  • [4] Tumor markers are elevated in patients with rheumatoid arthritis and do not indicate presence of cancer
    Bergamaschi, Samuel
    Morato, Edelton
    Bazzo, Maria
    Neves, Fabricio
    Fialho, Sonia
    Castro, Glaucio
    Zimmermann, Adriana
    Pereira, Ivanio
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2012, 15 (02) : 179 - 182
  • [5] H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1
    Berteaux, N
    Lottin, V
    Monté, D
    Pinte, S
    Quatannens, B
    Coll, J
    Hondermarck, H
    Curgy, JJ
    Dugimont, T
    Adriaenssens, E
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (33) : 29625 - 29636
  • [6] A Novel H19 Antisense RNA Overexpressed in Breast Cancer Contributes to Paternal IGF2 Expression
    Berteaux, Nathalie
    Aptel, Nathalie
    Cathala, Guy
    Genton, Celine
    Coll, Jean
    Daccache, Anthony
    Spruyt, Nathalie
    Hondermarck, Hubert
    Dugimont, Thierry
    Curgy, Jean-Jacques
    Forne, Thierry
    Adriaenssens, Eric
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2008, 28 (22) : 6731 - 6745
  • [7] Decreased Placental Methylation at the H19/IGF2 Imprinting Control Region is Associated with Normotensive Intrauterine Growth Restriction but not Preeclampsia
    Bourque, D. K.
    Avila, L.
    Penaherrera, M.
    von Dadelszen, P.
    Robinson, W. P.
    [J]. PLACENTA, 2010, 31 (03) : 197 - 202
  • [8] The imprinted H19 noncoding RNA is a primary microRNA precursor
    Cai, Xuezhong
    Cullen, Bryan R.
    [J]. RNA, 2007, 13 (03) : 313 - 316
  • [9] Novel Biomarkers for Predicting Preeclampsia
    Carty, David M.
    Delles, Christian
    Dominciczak, Anna F.
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 2008, 18 (05) : 186 - 194
  • [10] Beckwith-Wiedemann Syndrome
    Choufani, Sanaa
    Shuman, Cheryl
    Weksberg, Rosanna
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2010, 154C (03) : 343 - 354